title: [Underlying conditions associated with the occurrence of retinal vein occlusion].
abstract: BACKGROUND
  Conventional risk factors for retinal vein occlusion (RVO) are well established through large epidemiological studies, but triggering factors remain poorly known.
  
  
  METHODS
  A prospective observational study through a questionnaire was completed between January and October 2009 by patients with RVO and controls.
  
  
  RESULTS
  Sixty-one patients, including 42 central retinal vein occlusions (CRVO) and 19 branch vein occlusions (BRVO) as well as 118 controls were included. Of the CRVO patients, 77% discovered visual loss upon awakening in contrast to only 33% of BRVO patients. The comparison between RVO and controls showed a higher proportion in the RVO group for (in order of the highest risk): migraine headache (CRVO, 21 %; BRVO, 47 %; controls, 13 %; p=0.008), hypertension (CRVO, 52%; BRVO, 63%; controls, 37%; p=0.012), glaucoma (CRVO, 33%; BRVO, 22%; controls, 16%; p=0.034), antiplatelet or anticoagulant medication (CRVO, 42%; BRVO, 33%; controls, 26%; p=0.074), hyperlipidemia, ocular trauma, sudden deafness, or vertigo. The prevalence was similar in both groups for body mass index, history of phlebitis or peptic ulcer, smoking habits, stress, fasting, dehydration, vasodilator intake, and altitude stay.
  
  
  CONCLUSIONS
  In addition to the already known risk factors, this study underlines certain underlying conditions or circumstances related to the onset of RVO, such as migraine. In CRVO, three-quarters of the patients on average discovered visual loss upon awakening, which may indicate that nocturnal events may play a significant role in the pathogenesis of the occlusion.
authors.affiliation: Service d'ophtalmologie de l'hôpital intercommunal de Créteil, université Paris-XII-Henri-Mondor, 40, avenue de Verdun, 94000 Créteil, France. julien.tilleul@free.fr
authors.forename: J
authors.initials: J
authors.lastname: Tilleul
authors.forename: A
authors.initials: A
authors.lastname: Glacet-Bernard
authors.forename: G
authors.initials: G
authors.lastname: Coscas
authors.forename: G
authors.initials: G
authors.lastname: Soubrane
authors.forename: E H
authors.initials: EH
authors.lastname: Souied
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D015992:Body Mass Index; D015897:Comorbidity; D005131:Eye Injuries / Q000453:epidemiology; D005260:Female; D005901:Glaucoma / Q000453:epidemiology; D006184:Habits; D003639:Hearing Loss, Sudden / Q000453:epidemiology; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000453:epidemiology; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000453:epidemiology* / Q000209:etiology; D012307:Risk Factors; D012890:Sleep; D019851:Thrombophilia / Q000453:epidemiology; D014717:Vertigo / Q000453:epidemiology
chemical_list: D000925:Anticoagulants